Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

NEW YORK–(BUSINESS WIRE)–$SDGR—Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. “We are very pleased to welcome Arun to our … [Read more…]

Mevion Selected to Equip Proton Center in Southern China

LITTLETON, Mass.–(BUSINESS WIRE)–#ProtonTherapy—Mevion Medical Systems announced today that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS) in a comprehensive hospital in Southern China. Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue … [Read more…]

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors according to their biologic risk of metastasis, consistent with findings in previous development … [Read more…]

Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting

– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, … [Read more…]

Alchemab Announces Publication of AntiBERTa, an Antibody-Specific Machine Learning Model with Multiple Applications

BOSTON & CAMBRIDGE, England–(BUSINESS WIRE)–Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components of an antibody amino acid … [Read more…]

More than two in five Americans are more sensitive to stress than before the pandemic

LifeWorks Mental Health Index™ reveals 42 percent of Americans are feeling an increased sensitivity to stress CHICAGO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its monthly Mental Health Index™ that showed the 42 percent of Americans feeling more sensitive to stress have a mental health score more than 10 … [Read more…]

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

— RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial — — 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate — — All patients showed clinical reversal of disease course, including statistically significant reduction in all-cause hospitalizations and incidence of severe infections — … [Read more…]

Viral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route … [Read more…]

Booba and Silent Seeds Announce the Launch of a New Strain of Cannabis (THC), the B-45!

PARIS–(BUSINESS WIRE)–Alexandre Lacarré, the co-founder of the Silent Seeds seed bank (formerly Dinafem) and the famous French rapper Booba, have announced a unique cooperation to create B-45, a seed specially designed for the artist. A first in Europe! With 20 years of experience and R&D, Silent Seeds was Booba’s partner of choice for the creation … [Read more…]

Global Intranasal Drug & Vaccine Delivery Market Research Report to 2027 – Rise in Number of Prescriptions for Non-invasive Drug Delivery Routes Presents Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intranasal Drug & Vaccine Delivery Market Research Report by Distribution Channel, Application, Product, Dosage, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Intranasal Drug & Vaccine Delivery Market size was estimated at USD 44.85 billion in 2021, USD 48.21 billion in … [Read more…]